Kornimate/medical-research-clean huggingface dataset:
the effects of pelvic floor muscle training applied with the telerehabilitation method in the postpartum period

Conditions: Pelvic Floor Disorders; Postpartum Disorder; Quality of Life; Mothers

Summary: pelvic floor muscle training (pfmt) is routinely recommended to treat and prevent pelvic floor symptoms in the postpartum period. however, due to the high cost, remoteness of the location, and responsibilities of the baby, women cannot participate in pfmt whenever and wherever they want. telerehabilitation (tr) may be an effective method to facilitate women's access to pfmt. therefore, our study aims to compare the short and medium-term effects of pfmt applied with the tr method on pelvic floor symptoms, symptom-related quality of life and pelvic floor muscle function with supervised pfmt. this randomized controlled study was conducted at yeditepe university hospital bağdat street polyclinic pelvic floor center and online synchronous platform on women aged 18-35 and between the 6th and 8th weeks postpartum. participants were randomly assigned to the synchronized pfmt performed with the telerehabilitation method (tr-pfmt) group and the supervised pfmt (s-pfmt) group. the same pfmt program was carried out in both groups for 45-50 minutes, 2 days a week for 8 weeks, by two physiotherapists specialized experienced in the pelvic floor. the program was carried out via a synchronous online platform (skype™ program) in the tr-pfmt group, and as a face-to-face session in the s-pfmt group. participants' pelvic floor symptoms were evaluated with the pelvic floor distress inventory-20 (pfdi-20), symptom-related quality of life was evaluated with the pelvic floor impact questionnaire-7 (pfiq-7), and pelvic floor muscle function was evaluated with superficial electromyography. evaluations were made 3 times in total: before the exercise program, after the exercise program and at the 8th week after the exercise program (6th month postpartum).


Eligibility criteria:
inclusion criteria: * being a woman between 18-35 years old * between the 6th and 8th weeks postpartum * native turkish * having the appropriate technological infrastructure to participate in an exercise session via the internet (for the tr-pfmt group) exclusion criteria: * number of births \>2 * the week of pregnancy \<32 * having a history of 3rd and 4th-degree perineal tears * cesarean birth * inability to contract the pelvic floor muscle (pelvic floor muscle strength ≤2 according to the modified oxford scale) * the electromyography values of the abdominal muscles or hip adductors during contraction of the pelvic floor muscles are more than 10 microvolts * the presence of neurological, orthopedic, psychiatric, hematological or cardiovascular disease that would prevent pfmt as questioned by the gynecologist * body mass index ≥ 25 kg/m² * the presence of active urinary tract or vaginal infection in the last week

Keywords: pelvic floor muscle training postpartum telerehabilitation quality of life
thermal imaging in neonates: a feasibility study in healthy babies and babies with suspected ttn

Conditions: Thermal Imaging, Neonatal Pneumonia, Tachypnea

Summary: this is a study to evaluate thermal imaging as a technology to monitor the normal clearing of amniotic fluid from healthy newborns and newborns suspected of having a condition called transient tachypnea of the newborn, or ttn. thermal images are taken using an imaging device that attaches to an iphone. this device, commercially known as flir one, creates a non-identifiable image based on the heat pattern of an object. in this case, the object is a child's chest and back. it does not emit any radiation like an x-ray does.


Eligibility criteria:
inclusion criteria (healthy and suspected ttn babies): * full term (greater than or equal to 37 weeks gestation) * less than 3 days old * born via normal vaginal delivery inclusion criteria (only for suspected ttn babies): * neonatologist assesses baby as possibly having ttn * chest x-ray done as part of evaluation for ttn * no other significant co-morbid conditions present exclusion criteria: * parents do not consent to have baby participate

Keywords: healthy neonate, tachypnea, thermal imaging, pneumonia
post-release retention in hiv care for ex-inmates in south africa

Conditions: Hiv; Adherence, Patient

Summary: hiv remains the leading cause of death in south africa as a result of a failure of people living with hiv to seek hiv treatment and be retained in care. after initiating antiretroviral therapy while incarcerated, most ex-inmates fail to remain engaged in care. the goal of this research is to reduce mortality, morbidity, and hiv transmission by developing an actionable approach to retaining these individuals in hiv care.

to pilot a randomized clinical trial (rct) of a transition adherence club (tcac) versus traditional care, among ex-inmates receiving antiretroviral therapy in south africa, to study feasibility, acceptability, and preliminary effectiveness using mixed methods. investigators will pilot an rct of the tcac compared to traditional care among inmates/ex-inmates measuring transition in care, six-month viral load suppression, and follow-up of participants. feasibility will be assessed by process measures. acceptability will be assessed using in-depth interviews among 36 participants and 10 staff. effectiveness will be assessed by a difference in proportions in-care with an undetectable viral load at 6 months and difference in bonding social capital and care satisfaction between arms.

Eligibility criteria:
inclusion criteria: * currently incarcerated (either an offender/sentenced inmates or awaiting trial inmate/remandee) * housed at one of the study correctional facilities (including participating satellite centres) * diagnosed with hiv * currently receiving antiretroviral therapy * anticipated release or trial date within 3 months of study enrollment * self-report expected to reside within ekurhuleni, tshwane, or johannesburg districts of gauteng province and within proximity to one of the tcac sites (within 20 km, 45 minute travel time, or two local taxi minibus rides) * agree to post-discharge follow-up * medically stable based on dcs health assessment (including not pregnant) * on antiretroviral therapy (art) for \>3 months at the expected time of corrections release exclusion criteria: * failure to provide informed consent to be followed up by study staff after release * unable to speak one of the study languages (english, sesotho, isixhosa, isizulu, setswana, xitsonga, and afrikaans)

Keywords: incarceration linkage to care retention in care
effects of a food supplement composed by biointestil ® (bionocol®) on microbiota and inflammatory profile in irritable bowel syndrome patients

Conditions: Irritable Bowel Syndrome

Summary: the aim of this double blind placebo-controlled study is to evaluate the effect of biointestil on fecal microbiota, inflammatory chemokines and symptoms in patients affected by irritable bowel syndrome (ibs).

biointestil is a dietary supplement based on palmrose oil (cymbopogon martinii) and ginger ryzoma powder. palmrose oil effects were already established in animal model of colitis and in a pilot study on patients with ibs. in this study, 108 patients will be randomized to receive biointestil or placebo in a 1:1 ratio, for four weeks. fecal and blood samples will be collected at each visit for microbiota and chemokine analysis, patients syntoms will be evaluated by administration of the validated ibs-vas.

Eligibility criteria:
inclusion criteria: * willing of sign written informed consent; * participants affected with irritable bowel syndrome (ibs) who satisfy rome iii criterias for diagnosis * body weight between 48 and 104 kg, with a bmi less than 27 * age between 18 and 65 years old exclusion criteria: * participants that have not taken following medications within 30 days before randomization: steroidal anti-inflammatory drugs, antibiotics or supplemntes or functional foods that may contain probiotics or prebiotics * women who suspect to be/are pregnant or in lactacy * participants with inflammatory bowel disease disgnosis or celiac disease or severe systemic disease * participants who are intolerant to lactose or with food allergies confirmed * particpiants with confirmed or suspected hypersensibility to one or more of bionocol® components * participants with severe concomitants disease that, by investigator's opinion, interfere with study partecipation * participants under anticoagulant therapy or with coagulation disease * participants with renal and hepatic failure * participants who have taken any investigational drug within 2 month the randomization visit

Keywords: microbiota immune system
motivational enhancement therapy to improve adherence to aromatase inhibitors

Conditions: Breast Cancer; Medication Adherence

Summary: the proposed research is a randomized controlled investigation of the efficacy of motivational interviewing (mi) to improve adherence to aromatase inhibitors (ai) in a community sample of patients with poor adherence to ais.

background: the use of aromatase inhibitors (ais) among breast cancer (bc) patients with hormone receptor-positive disease reduces recurrence by 41% and mortality by 31%. despite the efficacy of ais, one-quarter of bc survivors fail to take their ais as prescribed during the first year with another one-fifth discontinuing later in treatment. there are a variety of reasons for non-adherence, including low motivation, poor patient-provider communication, low self-efficacy, low perceived risk, and the experience of side effects. one promising intervention for improving treatment adherence is motivational interviewing (mi), a broad set of patient-centered techniques designed to enhance motivation for behaviour change. objectives: to conduct a parallel-group, double-blind, randomized controlled trial (rct) to evaluate the efficacy of mi at improving 12-month adherence to ais relative to attention control (ac). the primary outcome is medication adherence measured using pharmacy records and calculated by medication possession ratio (mpr). secondary outcomes include self-reported adherence, motivation and self-efficacy. methods: a community sample of bc survivors newly prescribed ais will be recruited from a local cancer centre pharmacy for a 6-month medication adherence observation period. the investigators chose to recruit new ai users because a significant number (i.e., 20-35%) are expected to discontinue medication within 12-months. mpr will be calculated following the observation period and patients meeting inclusion criteria and deemed non-adherent (mpr \< 80%) will be enrolled in the trial, randomly assigned to mi or ac, and scheduled for a baseline appointment. recruitment will continue until 128 (64 per group) non-adherent bc survivors are identified. four mi or ac sessions will be delivered at 3-month intervals (0-,3-,6-,9-months), each lasting 30-45 minutes. a final assessment will occur at 12-months. baseline and final assessments will be conducted by an assistant who is not affiliated with the trial. given that the long-term adherence to ais is poor, a lack of adherence leads to clinically meaningful increases in bc recurrence, morbidity and mortality, and there has been only one published intervention study related to ais to date, our trial represents a top priority in the prevention and treatment of bc.

Eligibility criteria:
inclusion criteria: * english-speaking women, prescribed their first aromatase inhibitor medication. been identified as non-adherent following a 6-month observation run-in period (phase 1). exclusion criteria: * unable to comply with protocols; diagnosis of cognitive impairment; severe psychopathology (e.g., schizophrenia); history of drug abuse; terminal condition with low likelihood of survival; living in a long-term care facility.
the effects of scoliosis-specific exercises before surgery

Conditions: Adolescent Idiopathic Scoliosis

Summary: the aim of this study is to investigate the effects of scoliosis-specific exercises in adolescent idiopathic scoliosis patients, who had surgical indication, on functional capacity, cosmetic deformity perception, quality of life in postoperative period.

30 adolescent idiopathic scoliosis patients, who had surgery indication and aged between 10-18 years, will be included. the participants will be randomised into two groups. 15 patients will be included in the exercise group and 15 patients in the control group. in the exercise group, a total of 12 sessions of exercise are planned, 6 weeks before the surgery and 2 days per week. in the control group, the exercise protocol will not be performed before surgery. the outcomes will include the cosmetic deformity, quality of life, pain level, functional capacity, spine flexibility. in the exercise group, the evaluations will be made in the first interview (before exercise application), at the end of 6 weeks of exercise (when the exercise program is completed), in the early postoperative period and 12 weeks after surgery. evaluations in the control group will be carried out at the first interview, at the 6th week, in the early postoperative period, and at the 12th week postoperatively.

Eligibility criteria:
inclusion criteria: * diagnosed with adolescent idiopathic scoliosis * aged between 10 and 18 years * to have surgery indication exclusion criteria: * leg discrepancy * cervical region participation to curve * additional disease may cause respiratory problem

Keywords: adolescent idiopathic scoliosis preoperative rehabilitation surgery
intravenous versus oral administration of prednisolone in exacerbations of chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: treatment with systemic corticosteroids for acute exacerbations of copd results in the improvement of clinical outcomes. the optimal route of administration has not been rigorously studied in copd. upon hospitalization, corticosteroids are administered intravenously in many hospitals. oral administration is more convenient, though, because there is no need for intravenous access, less personnel is required for starting and monitoring therapy, and material costs are smaller. the investigators hypothesized that oral administration is not inferior to intravenous administration of prednisolone in the treatment of patients hospitalized for an acute exacerbation of copd.


Eligibility criteria:
inclusion criteria: * exacerbation of copd (at least global initiative for chronic obstructive lung disease \[gold\] severity stage ii) * smoking history of \> 10 pack years exclusion criteria: * signs of severe exacerbation (arterial ph \ 9.3 kpa) * history of asthma * significant or unstable co-morbidity * participated in another study 4 weeks before admission * previously randomized to this study * findings on chest radiography other than those fitting with signs of copd * known hypersensitivity to prednisolone * non-compliant

Keywords: copd exacerbations corticosteroids oral intravenous chronic obstructive pulmonary disease (copd)
ultrasound scores as indication of response to subcutaneous abatacept in subjects with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a chronic inflammatory disease (a long-lasting disease causing pain and swelling) associated with significant health problems. it is a difficult disease to manage as the disease is often unpredictable. ra causes inflammation (swelling) of the joints that can cause joint damage, deformity, and progressive disability and impairment. it is estimated that 1% of the world's population suffers from this disease. the purpose of this research study is to determine if a change in inflammation seen on the ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.


Eligibility criteria:
inclusion criteria: 1. over 18 years old 2. has a diagnosis of rheumatoid arthritis 3. stable dmards for at least 1 month (methotrexate, leflunomide, hydroxychloroquine, or sulfasalazine) 4. disease activity score das28/esr \> 3.2 or all must be met: tjc (tender joint count)\>=4, sjc (swollen joint count)\>=4 5. must be able to understand information in the informed consent and comply with study requirements 6. total ultrasound synovitis (inflammation of joint-lining membrane) power doppler score \>=1 for at least 2 joints and total synovitis score \>=1 for at least 1 joint exclusion criteria: 1. current or prior use of biologic drugs (tnf inhibitors, il-6 inhibitors, cd20 inhibitors, il-1 inhibitors, etc.) 2. pregnancy or breast feeding 3. daily prednisone \> 10mg (stable dose for at least 1 month) 4. intra-articular steroid injection of the wrist or joints within last 2 months 5. history of a concomitant autoimmune disease such as lupus, psoriatic arthritis 6. history of cancer 7. previous exposure to abatacept

Keywords: rheumatoid arthritis subcutaneous abatacept ultrasound
effects of music therapy on breastfeeding among mothers of premature newborns

Conditions: Breastfeeding

Summary: the purpose of this study is to evaluate the impact of music therapy on breastfeeding rates among mothers of premature newborns. hypothesis: music therapy applied to mothers of premature newborns increases the rates of maternal breastfeeding at the time of the infant hospital discharge and at follow-up visits.

music therapy has been shown to have positive effects in several areas such as mental health, special education, rehabilitation and social development. its use as a means to facilitate communication and expression of emotional contents was shown to be able to promote relief of anxiety, fears and tensions. however, in the maternal and child health area there are still few studies demonstrating the contribution of this therapy in the promotion of health and no study evaluating specifically the impact of this intervention on the rates of breastfeeding in mothers of premature newborns.

Eligibility criteria:
inclusion criteria: * mothers of premature newborns, with birth weight ≤ 1750 g that have reached clinical stability defined by the medical staff. * to have signed an informed consent to participate in the study. exclusion criteria: * mothers that are hiv (human immunodeficiency virus) positive. * mothers of neonates with clinical problems that impaired breast suction (encephalopathy with serious hypotonus, oro-facial anomalies, and heart problems). * mothers with severe hearing deficiencies. exit criteria: * mothers whose neonates died during the hospital stay. * mothers who, for any reason, had three or less music therapy sessions.

Keywords: breast feeding music therapy maternal welfare infant, newborn
low-dose vs high-dose iv cyclophosphamide for proliferative ln in children

Conditions: Renal Insufficiency; Infection

Summary: proliferative lupus nephritis (ln)is the predominant cause of morbidity and mortality in juvenile systemic lupus erythematosus (sle). induction therapy with high-dose intravenous cyclophosphamide can improve renal outcomes, but considerably associated with infection. although severe infection is the significant complication related to poorer prognosis for juvenile sle patients in asia, cyclophosphamide is still commonly used as the drug of choice for severe lupus nephritis. euro-lupus nephritis trial demonstrated low-dose intravenous cyclophosphamide regimen followed by azathioprine achieved good clinical results comparable with obtained high-dose regimen. there was lower number of severe infection episodes, but no significant difference. recent studies applied low dose of cyclophosphamide (500 mg/m2/dose or 500 mg/dose)in young patients and showed good renal response. low-dose intravenous cyclophosphamide regimen might promote non-inferior renal remission whereas decrease risk of serious infection and improve overall patient outcomes.


Eligibility criteria:
inclusion criteria: * child up to 15 years of age who fulfilled the 1997 updating the american college of rheumatology revised criteria for the classification of sle and his or her renal biopsy reveals lupus nephritis class iii or iv regarding to international society of nephrology/renal pathology society revision on the classification of the lupus nephritis. exclusion criteria: * patient who has prior renal insufficiency due to chronic kidney disease other than lupus nephritis * patient who has the history of cyclophosphamide hypersensitivity * patient who has prior cyclophosphamide or mycophenolate mofetil administration within 6 months * patient who is pregnant
mind-body approaches for medical conditions

Conditions: Rheumatoid Arthritis; Psoriasis; Heart Failure

Summary: chronic diseases are currently the most prevalent and most costly health conditions world-wide, and morbidity is expected to increase over coming years. factors such that increased life-expectancy and certain life style-related factors, such as smoking, high-fat diet and alcohol-consumption, are commonly associated with the increase in most of the common chronic diseases. however, more complex psychosocial factors such as depression, stress, work-related dynamics and thinking patterns are thought be associated with poor health status and impaired health related quality of life among patients with suffering from chronic physical conditions (i.e. a biopsychosocial approach). therefore, psychosocial intervention has been suggested as a complementary treatment strategy for patients with chronic conditions. the aim of this randomized trial is to evaluate the effectiveness of mind-body multidisciplinary rehabilitation on health-related quality of life, and disease specific endpoints in people with rheumatoid arthritis, psoriasis, or heart failure.


Eligibility criteria:
inclusion criteria: rheumatoid arthritis: * ra according to the 1987 revised american college of rheumatology criteria * not selected on the basis of their level of activity. * the treatment of both the ra and any other medical condition have to be stable and constant for at least three months at the time of enrolment, and no future planned changes of therapy exist at the time of inclusion. * oral corticosteroids, if used previously, will be allowed at a maximum prednisone dose with an equivalent of 10mg/day. psoriasis: * diagnosed plaque psoriasis for 6 months or longer * psoriasis medical condition have to be stable and constant for at least three months at the time of enrolment (i.e. no future planned changes of therapy exist at the time of inclusion). * exclusion criteria are other immune-mediated conditions requiring current systemic immunosuppressant treatment except psoriatic arthritis. heart failure with reduced ejection fraction: * symptomatic patients (nyha class ii or iii, or nyha class iv if crt planned at enrolment) with systolic heart failure (left ventricular ejection fraction ≤40%) will be considered eligible for enrolment. * the qualifying left ventricular ejection fraction (measured on stable heart failure medication). exclusion criteria: * ability to participate * psychopathology: persons with severe mental illness are excluded. * alcohol and/ or drug abuse * impaired cognitive functions